Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Price Down 5.8% – Time to Sell?

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) were down 5.8% during trading on Wednesday . The company traded as low as $10.32 and last traded at $10.33. Approximately 292,773 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 1,284,280 shares. The stock had previously closed at $10.97.

Analyst Ratings Changes

A number of research analysts have issued reports on BAYRY shares. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 23rd. DZ Bank cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

The firm’s fifty day simple moving average is $12.43 and its 200 day simple moving average is $9.88. The company has a market capitalization of $42.88 billion, a PE ratio of -9.83, a price-to-earnings-growth ratio of 4.36 and a beta of 0.69. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.18. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.The business had revenue of $13.24 billion during the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, research analysts predict that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.